Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis
ConclusionsWe found an increased risk of herpes zoster infection, and transient cardiovascular events among patients treated with sphingosine-1-phosphate modulators.Clinical Trial RegistrationPROSPERO CRD42020172575.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Cardiology | Cardiovascular | Clinical Trials | Conferences | Crohn's Disease | Databases & Libraries | Drugs & Pharmacology | Heart | Herpes | Inflammatory Bowel Disease | Lupus | Multiple Sclerosis | Psoriasis | Study | Ulcerative Colitis